TapImmune Inc. Signs Research and Technology License Option Agreement With Mayo Clinic for Smallpox Vaccine

SEATTLE, Aug. 4, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune's proprietary TAP technology. TapImmune also has an exclusive Option to the smallpox vaccine technology after research studies have been completed under the terms of the agreement.

Back to news